NCT02454556View on ClinicalTrials.gov

A Randomized, Multicentre, Open Label, Evaluator Blinded Study to Evaluate Safety and Efficacy of Folitime® of Gemabiotech S.A., Versus Gonal-f ® of Merck Serono, in Patients With Infertility Undergoing ART

PHASE3CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Infertility
Interventions
DRUG

FOLITIME®

DRUG

Gonal-F®

Trial Locations (1)

C1122AAF

Halitus Instituto Médico, Buenos Aires

Sponsors

Lead Sponsor

Gema Biotech S.A.
All Listed Sponsors
collaborator

QUID Quality in Drugs and Devices Latin American Consulting SRL

OTHER

lead

Gema Biotech S.A.

INDUSTRY